Unternehmensübersicht
Erasca, Inc. operates as a clinical-stage precision oncology enterprise dedicated to the discovery, development, and commercialization of novel therapies specifically targeting patients suffering from RAS/MAPK pathway-driven cancers. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself at the intersection of advanced pharmaceutical research and specialized cancer treatment modalities. Its current market capitalization stands at $4.65B, while the company employs a workforce of 103 individuals to advance its product pipeline, which includes the pan-RAS molecular glue candidate ERAS-0015. Although the company reports no available annual revenue figures in the provided data, its substantial market cap of $4.65B relative to a staff count of 103 suggests a valuation heavily weighted toward future potential rather than current cash generation, a common characteristic for early-stage biotechnology firms focused on high-risk, high-reward therapeutic candidates.
Finanzielle Gesundheit
The financial statements for Erasca, Inc. indicate a net income of $-124,546,000 and an EBITDA of $-128,298,000, reflecting significant operational losses typical of companies in the development phase. The absence of reported revenue (N/A) combined with these substantial negative earnings reveals a cost structure where expenses, likely driven by clinical trial costs and research and development, far exceed any current income streams. Free cash flow is reported at $-66,761,124, which signifies that the company is burning through cash reserves to fund its operations and pipeline advancement rather than generating liquidity from business activities. Consequently, the company possesses limited immediate financial flexibility and must rely on external capital markets or existing cash balances to sustain its operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that technically reflects the lack of recognized revenue in the available data rather than a specific cost efficiency metric. This zero-margin status precludes any traditional profitability analysis until revenue is recognized from product sales or licensing agreements. On the liability side, the company holds $276.08M in cash against $47.14M in debt, resulting in a debt-to-equity ratio of 14.50 which, while high, is partially mitigated by the substantial cash hoard. The current ratio stands at 10.04, indicating a highly liquid balance sheet where short-term assets significantly exceed short-term liabilities, providing a robust buffer against immediate repayment obligations. Return on Equity is -33.3% and Return on Assets is -18.3%, metrics that mathematically demonstrate that management is currently generating negative returns on the capital deployed by shareholders and the asset base. These negative return figures are consistent with the company's status as a pre-revenue biotechnology entity where capital expenditure is an investment in future potential rather than a driver of current profit.
Bewertungsanalyse
The valuation metrics for Erasca, Inc. present a unique picture given the lack of positive earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -27.64. The negative forward P/E implies that analysts or market participants are projecting future earnings that are still negative or that current valuation models must rely on non-earnings-based metrics due to the current loss position. The price-to-book ratio is calculated at 13.09, indicating that the market values the company at more than thirteen times its net asset value, suggesting a significant premium assigned to its intellectual property and pipeline potential over its book equity. Alternative valuation measures such as Price to Sales (N/A) and EV/EBITDA (-34.48) further illustrate that traditional multiple-based comparisons are not applicable in the conventional sense due to the absence of revenue and positive earnings. The stock has experienced extreme volatility, trading within a 52-week range between a low of $1.01 and a high of $16.41. Without a specific current price provided in the facts to calculate a percentage deviation, the historical range demonstrates a massive expansion in market value from the low point. The beta of 1.17 indicates that the stock's price volatility is 17% higher than that of the broader market, reflecting the inherent risk profile associated with clinical-stage biotechnology assets.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, which prevents a direct quantitative comparison between the pace of revenue expansion and earnings growth in the current reporting period. Since the company does not report positive revenue, the concept of earnings growing faster or slower than revenue does not apply in the traditional sense of profitable scaling but rather relates to the progression of clinical milestones and pipeline development. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it retains all available capital to fund research and development rather than distributing income to shareholders. This reinvestment strategy is standard for precision oncology companies in the clinical stage, prioritizing the advancement of therapies like ERAS-0015 over immediate shareholder returns. The overall growth and income profile is characterized by a reliance on capital appreciation driven by pipeline progress rather than dividends or established revenue streams, with the company currently operating in a phase of significant capital deployment before commercialization.